ORGO stock gains on a fresh price snapshot

Published on 09/18/2026 at 11:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ORGO stock traded at USD 13.67 on September 17, 2026, with a 64.63 percent gain in the cited analysis. Organogenesis also reported 2026 revenue of USD 440.0 million and adjusted EBITDA of USD 70.1 million.

ORGO, US68620V1026, Illustration mit AI erstellt.

ORGO stock (ISIN US68620V1026) traded at USD 13.67 in the cited analysis on September 17, 2026, after a 64.63 percent rise in the same report. Organogenesis Holdings Inc. is the company behind the ticker.

Reported figures still define the story

According to Investing.com, the referenced analysis said the shares reached USD 13.67 on September 17, 2026, and delivered a 64.63 percent return. That makes the stock move easy to read in one line: price and performance were both unusually strong in the cited snapshot.

For the latest reported period, Organogenesis said revenue was USD 440.0 million and adjusted EBITDA was USD 70.1 million in 2025, while full-year gross margin was 61.6 percent, according to the company. The same release also put 2025 net loss at USD 0.4 million, which was far smaller than the USD 11.1 million loss in 2024.

Margins matter more than momentum

That margin profile is the key comparison point for investors. Revenue of USD 440.0 million, adjusted EBITDA of USD 70.1 million and gross margin of 61.6 percent show a business that is still judged by operating efficiency, not only by the stock chart.

ORGO stock also has a clear historical anchor: the 2025 net loss of USD 0.4 million contrasted with the USD 11.1 million loss in 2024, which is a year-over-year improvement of USD 10.7 million. For a healthcare company with tissue and wound care exposure, that gap is the figure worth watching.

Price stays the focus

ORGO stock was quoted at USD 13.67 on September 17, 2026, and the same cited analysis framed the move as a 64.63 percent gain. Organogenesis stock therefore enters the new session with both a price rerating and a recent profitability backdrop.